Cytokinetics, Incorporated announced that the FDA has extended the action date for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM), to December 26, 2025. The extension is due ...
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance ...
Clene plans to submit a New Drug Application for CNM-Au8 in ALS by late 2025 and initiate a Phase 3 trial. Clene Inc. announced its plans to submit a New Drug Application (NDA) for CNM-Au8® for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback